Patents by Inventor Stewart Noble

Stewart Noble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9725697
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: August 8, 2017
    Assignee: The University Court of The University of Edinburgh
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Patent number: 9604242
    Abstract: A volatile liquid droplet dispenser for containing a liquid to be dispensed, with a first substrate having a space for containing the liquid, and having an outlet with at least one outlet nozzle, the first substrate further having the space adjacent to the liquid outlet, to receive the liquid such that the liquid may exit through at least one outlet nozzle of the outlet, a second substrate having a liquid inlet, and an actuating membrane arranged to actuate liquid in the space. The first substrate also has a fluidic channel interconnected to the space and arranged to laterally connect the liquid inlet to the space, thereby conveying the liquid to the space by way of lateral capillary action. The outlet is eccentric to the liquid inlet and in a vertical plane that is substantially the same or lower than the plane of the liquid inlet, depending on the liquid used.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 28, 2017
    Assignee: APTAR FRANCE SAS
    Inventors: Joseph Hess, Amir Feriani, Luciano Cravero, Stewart Noble, Victor Ques
  • Publication number: 20150240208
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Application
    Filed: May 11, 2015
    Publication date: August 27, 2015
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Patent number: 9078887
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 14, 2015
    Assignees: Kalypsys, Inc., Alcon Laboratories, Inc.
    Inventors: Steven P. Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Patent number: 9029145
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 12, 2015
    Assignee: The University Court of the University of Edinburgh
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Patent number: 8569300
    Abstract: The present invention relates to substituted tetrazolo[1,5-a]pyrazine compounds for Formula IX: as well as pharmaceutical compositions thereof, which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: October 29, 2013
    Assignee: Kalypsys Inc.
    Inventors: Allen Borchardt, Robert Davis, Stewart A. Noble
  • Publication number: 20130178498
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: June 28, 2012
    Publication date: July 11, 2013
    Applicant: KALYPSYS, INC.
    Inventors: Steven Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Publication number: 20130116279
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 9, 2013
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Publication number: 20130045975
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 21, 2013
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • Patent number: 8258154
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: September 4, 2012
    Assignee: Kalypsys Inc.
    Inventors: Steven Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Patent number: 8138205
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: March 20, 2012
    Assignee: Kalypsys, Inc.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • Patent number: 8080566
    Abstract: The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: December 20, 2011
    Assignee: Kalypsys, Inc
    Inventors: Mehmet Kahraman, Allen J. Borchardt, Robert L. Davis, Stewart A. Noble, James W. Malecha
  • Patent number: 8080563
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: December 20, 2011
    Assignee: Kalypsys
    Inventors: Steven P. Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Publication number: 20110257137
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: March 10, 2011
    Publication date: October 20, 2011
    Applicant: KALYPSYS, INC.
    Inventors: Allen Borchardt, Robert Davis, Clay Beauregard, Daniel Becker, Daniel Gamache, Stewart A. Noble, Mark Hellberg, Peter Klimko, Zhihai Qiu, Joseph Payne, John Yanni
  • Publication number: 20110256109
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 20, 2011
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Publication number: 20110237565
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: March 10, 2011
    Publication date: September 29, 2011
    Applicant: KALYPSYS, INC.
    Inventors: Allen Borchardt, Robert Davis, Stewart A. Noble
  • Patent number: 7915253
    Abstract: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: March 29, 2011
    Assignee: Kalypsys, Inc
    Inventors: Stewart A. Noble, Guy Oshiro, James W. Malecha, Cunxiang Zhao, Carmen K. Robinson, Sergio G. Duron, Michael Sertic, Andrew K. Lindstrom, Andrew K. Shiau, Christopher D. Bayne, Mehmet Kahraman, Boliang Lou, Steve P. Govek
  • Publication number: 20110036921
    Abstract: A volatile liquid droplet dispenser for containing a liquid to be dispensed, with a first substrate having a space for containing the liquid, and having an outlet With at least one outlet nozzle, the first substrate further having the space adjacent to the liquid outlet, to receive the liquid such that the liquid may exit through at least one outlet nozzle of the outlet, a second substrate having a liquid inlet, and an actuating membrane arranged to actuate liquid in the space. The first substrate also has a fluidic channel interconnected to the space and arranged to laterally connect the liquid inlet means to the space, thereby conveying the liquid to the space by way of lateral capillary action. The outlet is eccentric to the liquid inlet and in a vertical plane that is substantially the same or lower than the plane of the liquid inlet, depending on the liquid used.
    Type: Application
    Filed: June 23, 2006
    Publication date: February 17, 2011
    Applicant: MICROFLOW ENGUINEERING SA
    Inventors: Joseph Hess, Amir Feriani, Luciano Cravero, Stewart Noble, Victor Ques
  • Patent number: 7834004
    Abstract: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: November 16, 2010
    Assignee: Kalypsys, Inc
    Inventors: Stewart A. Noble, Guy Oshiro, James W. Malecha, Cunxiang Zhao, Carmen Robinson, Sergio G. Duron, Michael Sertic, Andrew K. Lindstrom, Andrew K. Shiau, Christopher D Bayne, Mehmet Kahraman, Boliang Lou, Steven P. Govek
  • Patent number: 7825256
    Abstract: The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W? are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: November 2, 2010
    Assignee: Kalypsys, Inc.
    Inventors: Timothy C. Gahman, Hengyuan Lang, Mark R. Herbert, Angelina M. Thayer, Christian A. Hassig, Stewart A. Noble, Russell D. Cousins, Hui Zhuang, Christopher R. Santos, Xiaohong Chen